These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 29098555

  • 1. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
    Zhou K, Wen F, Zhang P, Zhou J, Zheng H, Sun L, Li Q.
    Clin Transl Oncol; 2018 Jun; 20(6):768-774. PubMed ID: 29098555
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
    Okuma HS, Horinouchi H, Kitahara S, Asao T, Sunami K, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.
    Clin Lung Cancer; 2017 Mar; 18(2):234-240.e2. PubMed ID: 27867001
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, Li Q.
    Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH, Ding HY, Xin WX, Zhong LK, Xu GQ, Zhang B, Yang GN, Fang L.
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [Abstract] [Full Text] [Related]

  • 6. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A.
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B, Chen H, Shen J, Ye M.
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q, Tan C, Yi L, Wan X, Peng L, Li J, Luo X, Zeng X.
    PLoS One; 2021 Oct; 16(11):e0258605. PubMed ID: 34780478
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z.
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B.
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [Abstract] [Full Text] [Related]

  • 11. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L, Zhou Z, Zeng X, Tan C, Liu Q.
    Front Immunol; 2024 Dec; 15():1408928. PubMed ID: 39035009
    [Abstract] [Full Text] [Related]

  • 12. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.
    Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A.
    Cancer Treat Rev; 2011 May; 37(3):242-9. PubMed ID: 20709456
    [Abstract] [Full Text] [Related]

  • 13. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Luealon P, Khempech N, Vasuratna A, Hanvoravongchai P, Havanond P.
    Asian Pac J Cancer Prev; 2016 May; 17(2):799-805. PubMed ID: 26925683
    [Abstract] [Full Text] [Related]

  • 14. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
    Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M, “Aktion Bronchialkarzinom” (ABC Study Group).
    J Thorac Oncol; 2012 Sep; 7(9):1432-9. PubMed ID: 22895140
    [Abstract] [Full Text] [Related]

  • 15. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K.
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
    Jiang L, Yang KH, Guan QL, Mi DH, Wang J.
    Intern Med J; 2012 Dec; 42(12):1297-309. PubMed ID: 22530708
    [Abstract] [Full Text] [Related]

  • 18. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
    Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH.
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K.
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
    Gong J, Wan Q, Shang J, Qian X, Su D, Sun Z, Liu G.
    Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.